ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents from the U.S. Patent and Trademark Office, bringing its total to 33 patents in the U.S. These patents include U.S. Patent No. 11456518, which covers manufacturing methods for a radio frequency applicator, and U.S. Patent No. 11478153, focusing on monitoring tissue temperature during surgical procedures. The company aims to enhance its thermoacoustic imaging systems and expand applications for its TAEUS technology, particularly in assessing liver health and temperature visualization during surgeries.

Positive

• Issuance of two new patents increases intellectual property protection.
• Patents support development of thermoacoustic imaging systems.
• Total of 33 patents enhances competitive positioning.

Negative

• None.

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that the United States Patent and Trademark Office has issued two new ENDRA patents, U.S. Patent No. 11456518 (the ‘518 patent) titled “Method for Manufacturing a Radio Frequency Applicator” and U.S. Patent No. 11478153 (the ‘153 patent) titled “System for Monitoring Tissue Temperature.”

“We are pleased with the issuance of our 32^nd and 33^rd patents in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "We continue to strengthen our intellectual property portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 56 patents issued globally.”

The ‘518 patent provides further intellectual property protection for our TAEUS platform related to its disruptive scanning approach. It covers a method for manufacturing a radio frequency (RF) applicator device that is used to provide reliable RF energy in a target region of tissue. Specifically, the '518 patent further defines ENDRA's innovative solution to provide targeted RF energy to tissue regions for certain applications, such as fat quantification of a patient's liver. The ‘518 patent is linked to its parent, U.S. Patent No. 10682059, which covers embodiments of the RF applicator device.

The ‘153 patent relates to the TAEUS system monitoring tissue temperature during surgical procedures. ENDRA expects its system to be effective for both thermotherapy and cryotherapy procedures. The ‘153 patent is linked to its parent, U.S. patent No. 10631734, which covers complementary method embodiments.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA’s ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; and ENDRA’s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005896/en/

Irina Pestrikova

Senior Director, Finance

investors@endrainc.com

www.endrainc.com

Investor Relations:

Yvonne Briggs

LHA Investor Relations

(310) 691-7100

YBriggs@lhai.com

Source: ENDRA Life Sciences Inc.

FAQ

What is the significance of the new patents issued to ENDRA Life Sciences Inc. (NDRA)?

The new patents enhance ENDRA's intellectual property portfolio, supporting its development of thermoacoustic imaging technology.

How many patents does ENDRA Life Sciences currently hold?

ENDRA Life Sciences holds a total of 33 patents in the U.S.

What technologies are covered by the new patents for NDRA?

The patents cover a radio frequency applicator manufacturing method and a system for monitoring tissue temperature.

How does ENDRA's TAEUS technology benefit healthcare?

TAEUS technology provides a cost-effective method for visualizing tissue and assessing liver health, addressing unmet clinical needs.